Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 25, 2020 08:00 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Announces Clinical Collaboration to Evaluate SB 11285 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

HOPKINTON, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and...
February 14, 2020 09:36 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Pharmaceuticals Reports 2019 Fourth Quarter and Full-Year Financial Results

HOPKINTON, Mass., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
January 29, 2020 08:30 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Discontinues Development of Inarigivir for the Treatment of HBV

Continuing to focus on immuno-oncology & inflammation, including IV STING agonist clinical program, oral STING antagonist platform and STING agonist ADCsAdjusting cost structure to fund operations...
December 26, 2019 06:00 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Stops Dosing of Inarigivir Patients in Phase 2 Program

HOPKINTON, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
December 09, 2019 08:00 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank to Present Data on its Novel Chimeric Antisense Oligonucleotide Compounds for Hepatitis B at HepDART 2019

HOPKINTON, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
November 20, 2019 09:00 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Announces Dosing of Patients in Phase 1 Clinical Trial of IV-Administered STING Agonist, SB 11285

HOPKINTON, Mass., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
November 12, 2019 08:00 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Announces Investor Conference Presentations for the Remainder of 2019

HOPKINTON, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
November 07, 2019 16:30 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Pharmaceuticals Reports Third Quarter 2019 Financial and Operational Results and Provides Corporate Update

HOPKINTON, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
October 17, 2019 08:00 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Announces Interim Top-Line Results from the First Cohort of the Phase 2 Trial Evaluating Low-Dose Inarigivir Plus Vemlidy® in Chronic Hepatitis B Patients

7 of 30 patients were HBsAg responders with ≥ 0.5log₁₀ reduction Inarigivir 50mg plus Vemlidy® 25mg was generally safe and well tolerated at 12 weeks Evaluation of inarigivir 200mg and 400mg...
September 23, 2019 08:00 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York, NY

HOPKINTON, Mass., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...